جست‌وجوی استاد و پژوهشگر

Noor Gammohمشاهده پروفایل

دانشیار

• Autophagy
• Glioblastoma Research
• Cancer Signaling Pathways
• +۳ مورد دیگر

Noor Gammoh is a CRUK Career Development Fellow and UoE Reader at the University of Edinburgh's Institute of Genetics and Cancer within the College of Medicine and Veterinary Medicine. She leads the Brain Cancer Survival Pathways research group focusing on autophagy mechanisms in glioblastoma. Her laboratory operates from the Edinburgh Cancer Research Centre at the Western General Hospital. Her research centers on autophagy regulation in cellular stress responses and its dual role in neurodegenerative diseases and cancer progression. Key areas include: Mechanistic studies of autophagy in brain tumor survival pathways PDGFRA-dependent oncogenic signaling interactions with autophagy Lysosomal degradation processes in glioblastoma Therapeutic targeting of autophagy components (ATG5, ATG16L1, LC3) Analysis of her recent publications reveals a strong focus on brain cancer therapeutic resistance mechanisms , particularly how autophagy supports PDGFRA-driven glioblastoma progression through metabolic adaptation and signaling modulation. Her work increasingly integrates CRISPR screening with in vivo RCAS glioma models to identify novel therapeutic targets. Award highlights include: CRUK Career Development Fellowship (2017-2024) Carnegie Trust Research Incentive Grant (2016) Chancellor's Fellowship (2013-2018) £1.64m Cancer Research UK grant for brain tumor research Edinburgh Stars of the Year recognition (2017) Gammoh actively mentors PhD students and postdoctoral fellows while securing significant funding from Cancer Research UK, BBSRC, and MRC. Her current project Characterise Novel Functions of a V-ATPase Complex Component in Lysosomal Lipase Activity (2024-2028) represents cutting-edge work on lysosomal metabolism in cancer. Her laboratory maintains strong collaborations with the Institute of Genetics and Molecular Medicine and utilizes advanced techniques including in vitro lipidation assays and autophagy monitoring systems.

Alexander von Kriegsheimمشاهده پروفایل

استاد

• Proteomics
• Mass Spectrometry
• Cancer Signaling Networks
• +۶ مورد دیگر

Dr. Alexander von Kriegsheim is a Professor at the University of Edinburgh , leading the Network Biology and Proteomics group at the Institute of Genetics and Cancer. His research combines mass spectrometry and systems biology to identify vulnerabilities in cancer signaling networks, with a focus on tumor initiation, ISGylation, and hypoxia signaling. He also develops technologies for drug target deconvolution and collaborates globally.

Ashton Faulknerمشاهده پروفایل

مدرس

• Cardiovascular Molecular Metabolism
• Endothelial Cell Biology
• Metabolic Substrate Trafficking
• +۷ مورد دیگر

Dr. Ashton Faulkner is a Lecturer in Biomedical Sciences at the Royal Veterinary College (University of London), specializing in cardiovascular molecular metabolism. His research focuses on how metabolic sensors regulate cellular function in vascular cells and how these mechanisms are altered in cardio-metabolic diseases. Key affiliations include: Cardiovascular and Renal Biology Research Group, Biochemical Society Ambassadorship. His work integrates molecular biology, metabolic regulation, and vascular physiology to develop novel therapies for cardiovascular protection and repair. Research Themes Mechanistic studies of fatty acid trafficking in vascular cells Redox and mitochondrial function in diabetic cardiovascular complications Pericyte biology for vascular and valve engineering Role of microRNAs in calcification inhibition Multi-omics approaches to diabetic heart disease Scientific Leadership Local Biochemical Society Ambassador (3-year term) Contributor to BSc Biological Sciences teaching Supervisor for BSc and MSci research projects

Emma E Vincentمشاهده پروفایل

استاد

• Molecular Metabolism
• Cancer Epidemiology
• Mendelian Randomization
• +۵ مورد دیگر

Professor Emma E Vincent serves as Professor of Molecular Metabolism at Bristol Medical School, University of Bristol, and holds a Research Fellowship at the School of Cellular and Molecular Medicine. Her work bridges molecular metabolism and cancer epidemiology, specifically investigating how type 2 diabetes (T2D) and obesity drive cancer development through metabolic reprogramming. Her educational background includes a BSc from the University of Nottingham and a PhD from the University of Bristol. Dr. Vincent's research centers on causal metabolic pathways linking T2D to site-specific cancers, with primary focus on colorectal and pancreatic cancers. She employs Mendelian randomization to isolate causative metabolic traits from T2D's heterogeneous profile, followed by laboratory validation using Stable Isotope Tracer Analysis and extracellular flux analysis to measure tumor cell metabolism. Her mission targets the development of T2D-specific cancer prevention strategies by identifying metabolic drivers of tumorigenesis. Recent publications reveal strong trends in obesity-cancer causal inference, particularly adiposity distribution effects across 12 cancer types and proteogenomic identification of molecular mediators like GREM1 in colorectal cancer. This work consistently applies genetic epidemiology to deconstruct metabolic contributions to oncogenesis. She has supervised 9 postgraduate students, including Dr. Emma Hazelwood (PhD on obesity-colorectal cancer relationships), and currently leads the £1.2M project 'The causal role of ketone bodies in obesity-associated disease risk' (2024-2027) as Principal Investigator. Her grant portfolio includes collaborations with international consortia on Mendelian randomization methodologies. Dr. Vincent operates within the Bristol Population Health Science Institute cancer research cluster, directing a multidisciplinary team that integrates genetic epidemiology with cellular metabolism studies. Her laboratory maintains active partnerships with McGill University (where she previously held postdoctoral positions) and global cancer genomics initiatives.

• Acute Myeloid Leukemia
• Stem Cell Research
• Hematopoietic Stem Cell Biology
• +۵ مورد دیگر

Professor Tim Somervaille serves as a Senior Group Leader at the Cancer Research UK Manchester Institute, which is part of the University of Manchester's Faculty of Biology, Medicine and Health. His research focuses on myeloid malignancies, particularly acute myeloid leukemia (AML), with significant contributions to understanding stem cell biology, transcriptional regulation, and enhancer regions in leukemia pathogenesis. His research interests span several critical areas in hematology and oncology, with particular emphasis on acute myeloid leukemia , stem cell biology , and transcriptional regulation in cancer . His work explores how dysregulation of transcription factors like RUNX1, GFI1, and LSD1 contributes to leukemia development, with specific focus on enhancer regions and epigenetic mechanisms that block cellular differentiation. His fingerprint analysis shows strong expertise in myeloid biology (100%), acute myeloid leukemia (68%), stem cell research (42%), enhancer regions (27%), LSD1 function (24%), and hematopoietic stem cell biology (22%). Analysis of his recent publications reveals a strong focus on myeloid malignancies, particularly chronic myelomonocytic leukemia and myelofibrosis. His work combines multi-omics approaches to understand disease heterogeneity, metabolic reprogramming, and immune dysregulation in these conditions. He has contributed significantly to clinical guidelines through the British Society for Haematology, demonstrating the translational impact of his research from basic science to clinical practice. Professor Somervaille has supervised 15 research projects and has been actively involved in collaborative research, including the NIHR Biomedical Research Centre: Cancer Precision Medicine Theme project (2017-2019). His work contributes to UN Sustainable Development Goals related to good health and well-being, particularly through cancer research and precision medicine approaches. He maintains an active research program with 77 publications to date, including high-impact articles in journals like Cell Reports Medicine and Leukemia. His datasets on transcriptional regulation in AML have garnered significant attention across social media and news outlets, demonstrating the broader impact of his work beyond traditional academic circles.

Peter Arthur-Farrajمشاهده پروفایل

پژوهشگر ارشد

• Peripheral Nerve Repair
• Schwann Cell Biology
• Neuroregeneration
• +۸ مورد دیگر

Peter Arthur-Farraj holds a Visiting Scientist position at the University of Cambridge and is a visiting senior research fellow at the Blizard Institute, Queen Mary University of London. He leads a research group focused on neuron-glia crosstalk in peripheral nervous system development, disease, and repair/regeneration. Research Affiliation: Blizard Institute, Queen Mary University of London Visiting Affiliation: University of Cambridge Techniques: Transgenic mice, zebrafish models, live imaging, cell coculture, transcriptomics/epigenomics His research spans peripheral nerve repair , Schwann cell biology , and neuroregeneration , with a particular emphasis on cellular and molecular mechanisms underlying nerve damage and recovery. He also explores translational approaches for cell and gene therapies in nerve repair and precision small molecule neuroablative treatments. The 15 most recent publications reflect a consistent focus on Schwann cell dynamics , axon degeneration/regeneration , and epigenetic regulation . Key trends include the role of c-Jun in nerve repair, myelination mechanisms, and clinical studies on neurological complications of SARS-CoV-2 vaccination and COVID-19 . Arthur-Farraj collaborates extensively across institutions, including University of Cambridge , Queen Mary University of London , and international partners like Hugo Cabedo (Universitat Miguel Hernández) and Robin JM Franklin (University of Cambridge). His work bridges basic science and clinical neurology , with a strong translational focus.

Laura Deardenمشاهده پروفایل

پژوهشگر ارشد

• Developmental Biology
• Neuroscience
• Molecular Biology
• +۴ مورد دیگر

Dr Laura Dearden is a Royal Society Dorothy Hodgkin Fellow at the Institute of Metabolic Science, University of Cambridge, specializing in developmental programming of metabolic disorders. Her research focuses on maternal obesity's molecular mechanisms affecting fetal hypothalamic development and long-term obesity risk. Dorothy Hodgkin Fellowship recipient 2023 Rank Prize New Lecturer Award Sir Henry Wellcome Post-doctoral Fellowship (2015-2020) She investigates insulin and miRNA roles in intergenerational obesity transmission using mouse models. Key areas include: Hypothalamic development in metabolic regulation Epigenetic modifications from maternal diets Sex-specific metabolic programming Translational interventions for maternal-fetal health Her recent publications (2023-2025) emphasize miRNA expression patterns, DNA methylation dynamics, and insulin signaling in fetal programming of cardiometabolic disorders. She collaborates with Prof Susan Ozanne and NIH partners. Senior research technician: Wai Ping Wong Postdoctoral researchers: Rosanne Chong, Matt Higgins NIH Oxcam PhD student: Keyshla Negron

Florian Merkleمشاهده پروفایل

دانشیار

• Neurological Diseases
• Obesity
• Human Pluripotent Stem Cell Biology
• +۶ مورد دیگر

Dr. Florian Merkle is an Associate Professor at the University of Cambridge in the Department of Pharmacology , where he leads the Merkle Laboratory . His work bridges human pluripotent stem cell (hPSC) biology , neurogenetics , and mouse modeling to investigate mechanisms of obesity , neurodegenerative diseases , and hypothalamic dysfunction . He is affiliated with the MRC Metabolic Diseases Unit , Wellcome Trust , and the Chan Zuckerberg Initiative . Academic Rank: Associate Professor Key Affiliations: University of Cambridge, MRC Metabolic Diseases Unit, Cambridge Stem Cell Institute, Chan Zuckerberg Initiative Research Interests Dr. Merkle’s research focuses on human-specific mechanisms of disease using hPSC-derived hypothalamic neurons and animal models. His team employs CRISPR/Cas9 genome editing , single-cell transcriptomics , high-content imaging , and mTORC1 signaling analysis to study: Cellular models of obesity and diabetes to identify novel anti-obesity drugs Shared mechanisms between metabolic and neurodegenerative diseases (e.g., Alzheimer’s, prion diseases) Genetic stability of hPSCs during long-term culture and differentiation Scientific Awards His accolades include: New York Stem Cell Foundation – Robertson Investigator Sir Henry Dale Fellow (Wellcome Trust & Royal Society) Ben Barres Investigator (Chan Zuckerberg Institute) Academy of Medical Sciences Springboard scheme Students & Collaborations Dr. Merkle co-supervises PhD student Pratik Koppikar (with NIH’s Michael Ward) and collaborates with experts in neuroscience (e.g., Giles Yeo, Giovanna Mallucci) and metabolism (e.g., Stephen O’Rahilly, Clemence Blouet). His lab is funded by the Royal Society , Wellcome Trust , and Chan Zuckerberg Initiative . Labs & Techniques The Merkle Lab utilizes hPSC differentiation , machine learning-assisted behavioral phenotyping , multi-omics integration , and in vivo physiology to bridge genetic data with organismic phenotypes . Their work aims to develop safe neuroprotective strategies and improve reproducibility in stem cell research .

Stephen O'Rahillyمشاهده پروفایل

استاد

• Endocrinology
• Metabolic Diseases
• Human Genetics
• +۳ مورد دیگر

Professor Sir Stephen O'Rahilly is a leading endocrinologist at the University of Cambridge, affiliated with the Department of Clinical Biochemistry and the Institute of Metabolic Science . He serves as Director of the MRC Metabolic Diseases Unit (2013–2029) and Principal Investigator of the Wellcome Discovery Research Platform (2024–2031). His research spans three major areas: (a) insulin resistance and metabolic disease (funded by Wellcome), (b) disorders of appetite and obesity with a focus on the leptin-melanocortin axis and GDF15's role in pregnancy sickness (MRC-funded), and (c) body composition regulation in diseases like cachexia (MRC and Cancer Grand Challenge Fund). Collaborators include David Savage, Tony Coll, and Giles Yeo. A pioneer in human genetics and translational research, he employs multidisciplinary approaches from cellular/murine models to clinical trials, guided by genetic insights from colleagues like John Perry, Ken Ong, and Nick Wareham. His work integrates metabolic and endocrine sciences to address obesity, diabetes, and related disorders. Scientific Awards : Harveian Oration (2016), Wellcome Investigator Fellow

John R B Perryمشاهده پروفایل

استاد

• Human Genetics
• Metabolic Disorders
• Reproductive Aging
• +۵ مورد دیگر

Professor John R B Perry is a human geneticist affiliated with the Institute of Metabolic Science and the MRC Epidemiology Unit at the University of Cambridge. He serves as a MRC Programme Leader and Director of Studies (Medicine) at King’s College Cambridge. His research integrates population-scale genetics with experimental validation to elucidate mechanisms underlying metabolic diseases and reproductive aging. Institute of Metabolic Science, University of Cambridge MRC Epidemiology Unit, University of Cambridge King’s College Cambridge (Fellow and Director of Studies) His work focuses on genome-wide genetic screens to identify genes influencing metabolic health, with particular interest in early-life exposures and reproductive aging . He employs Mendelian randomization to infer causal relationships between biomarkers and disease outcomes, and collaborates extensively to validate genetic findings through cellular and animal models . Key themes include obesity genetics, proteomic aging markers, and causal pathways linking metabolic and reproductive health. Recent publications highlight his expertise in multi-omics approaches to metabolic research, with studies on branched-chain amino acids , hypothalamic neuronal mapping , and coding variant contributions to disease heritability. His team actively develops polygenic risk scores and investigates developmental origins of metabolic traits . Contact: jrbp2@cam.ac.uk | Perry Lab Website

Helle Jørgensenمشاهده پروفایل

پژوهشگر ارشد

• Vascular Biology
• Atherosclerosis
• Epigenetics
• +۳ مورد دیگر

Dr. Helle Jørgensen is a British Heart Foundation Senior Basic Science Research Fellow at the Victor Phillip Dahdaleh Heart & Lung Research Institute , University of Cambridge. Her research focuses on vascular smooth muscle cell (VSMC) plasticity and heterogeneity in cardiovascular diseases, particularly atherosclerosis. Key Affiliations: Victor Phillip Dahdaleh Heart & Lung Research Institute Research Interests She investigates how VSMCs transition from a contractile state to proliferative/migratory phenotypes in disease contexts, using: Single-cell transcriptomics Lineage tracing Epigenetic profiling Genetic disease models Her work has revealed clonal expansion patterns in atherosclerotic lesions and characterized disease-specific VSMC subpopulations. Scientific Contributions 2025: Identified novel mechanosensitive pathways in VSMC expansion 2024: Elucidated epigenetic mechanisms regulating VSMC phenotypic switching 2023: Validated network-based approaches to target disease-associated VSMC regulators 2022: Characterized oligoclonal VSMC dynamics in cardiovascular disease 2021: Demonstrated senescence-induced resistance to VSMC re-differentiation Awards British Heart Foundation Senior Basic Science Research Fellow Collaborations Her research involves collaborations with: Prof. Martin R. Bennett (Vascular Biology) Dr. Mikhail Spivakov (Epigenetics)

Matthew Hoareمشاهده پروفایل

استادیار

• Hepatology
• Cancer Biology
• Cellular Senescence
• +۱۱ مورد دیگر

Dr. Matt Hoare is an Assistant Professor of Hepatology at the University of Cambridge, affiliated with the Early Cancer Institute and Addenbrooke's Hospital. His work bridges clinical hepatology with fundamental research on liver carcinogenesis, focusing on cellular senescence, somatic mutations, and tumor microenvironment dynamics in hepatocellular carcinoma (HCC). Department of Oncology, University of Cambridge Department of Medicine, University of Cambridge Early Cancer Institute, Cambridge Biomedical Campus Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust Research explores how senescent cell secretomes drive liver disease progression, with key discoveries in NOTCH1 and COX2 regulation of tumor initiation. Recent work deciphers genomic consequences of chronic liver disease, revealing clonal expansion patterns and cancerisation field effects. Publications highlight mechanistic studies on RAS titration, LGR5 targeting, and metabolic-genomic interactions in liver pathology. Clinical contributions include the East of England HCC service and trials in HCC management.

• Skeletal Myogenesis
• Developmental Biology
• Regenerative Medicine
• +۴ مورد دیگر

Giulio Cossu is the Constance Thornley Professor of Regenerative Medicine at the University of Manchester, affiliated with the Division of Cell Matrix Biology & Regenerative Medicine. His career spans multiple institutions, including the University of Rome, San Raffaele Stem Cell Research Institute, and University College London. He is renowned for pioneering skeletal myogenesis research and the first clinical trials using stem cells for muscular dystrophy.

Madeline Lancasterمشاهده پروفایل

استاد

• Human Brain Development
• Cerebral Organoids
• Neurodevelopmental Disorders
• +۵ مورد دیگر

Professor Madeline Lancaster serves as an Affiliate Professor at the Cambridge Stem Cell Institute and Group Leader in the Cell Biology Division of the Medical Research Council (MRC) Laboratory of Molecular Biology at the University of Cambridge. With her laboratory situated on the Cambridge Biomedical Campus, she leads pioneering research in human brain development using cerebral organoid technology she helped establish during her postdoctoral work at the IMBA in Vienna. Dr. Lancaster completed her biochemistry studies at Occidental College in Los Angeles before earning her PhD in biomedical sciences from the University of California, San Diego in 2010. Her groundbreaking work developing the first brain organoids began during her postdoctoral training in the Knoblich lab at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences, where she established the foundational techniques for cerebral organoid culture. She joined the MRC Laboratory of Molecular Biology in 2015 where she continues to advance this technology. Her research program focuses on understanding the fundamental differences between human brain development and that of other mammalian species, examining what makes human brain development unique. The Lancaster lab utilizes cerebral organoids - 3D tissues generated from stem cells that model human brain development in vitro - to investigate neurodevelopmental disorders including autism and intellectual disability, while also conducting comparative evolutionary studies to identify factors involved in human brain size expansion. Analysis of her recent publication record reveals a clear trajectory toward increasingly sophisticated organoid models with enhanced physiological relevance, including air-liquid interface systems, vascularized models, and assembloids that better capture neural circuitry. Her work spans fundamental developmental biology, disease modeling, and cross-species evolutionary comparisons, with growing emphasis on functional maturation and electrophysiological properties of organoid systems. As a Group Leader, Professor Lancaster mentors a diverse research team including postdoctoral researchers and graduate students working across multiple projects related to brain development and disease. Her laboratory maintains strong collaborations across the Cambridge research community and internationally, contributing significantly to the development of organoid technology standards and applications. The Lancaster lab operates within the advanced research environment of the MRC Laboratory of Molecular Biology, utilizing cutting-edge facilities including bioinformatics, electron microscopy, genomics, imaging, and single-cell platforms available through the Cambridge Stem Cell Institute core facilities. Her work continues to push the boundaries of what organoid models can reveal about human-specific aspects of brain development and disease.

James Nathanمشاهده پروفایل

استاد

• Oxygen Sensing
• Chromatin Modifications
• Hypoxia Inducible Factor (HIF) Pathway
• +۴ مورد دیگر

Professor James Nathan is affiliated with the University of Cambridge through the Cambridge Institute for Therapeutic Immunology & Infectious Disease (CITIID) and Cambridge Stem Cell Institute . His research focuses on cellular oxygen/nutrient sensing mechanisms, particularly their role in epigenetic regulation, transcriptional pathways, and disease progression. Key Research Areas: Oxygen-sensitive enzymes (HIF pathway, PHDs, TETs) Chromatin modifications by metabolite availability Metabolic regulation of immunity and cancer Mitochondrial metabolism in hypoxia responses Epigenetic control of gene expression Scientific Awards: Wellcome Trust Senior Clinical Fellow Technologies: Genome-wide mutagenesis screens Metabolic assays CRISPR-Cas9 functional genomics Single-cell analysis platforms His work has direct implications for inflammatory diseases, cancer therapeutics, and regenerative medicine, combining biochemical, genetic, and clinical approaches to bridge fundamental biology with translational applications.